Flow Cytometry Stem Cell Enumeration Kit Designed to Ease Stem Cell Transplantation
|
By LabMedica International staff writers Posted on 07 Mar 2012 |
|
Image: The BD Stem Cell Enumeration (SCE) Kit (Photo courtesy of BD Biosciences).
A dedicated flow cytometry stem cell enumeration kit is aimed at the rapidly growing stem cell transplantation market.
High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.
To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.
The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.
The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.
Related Links:
BD Biosciences
High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.
To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.
The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.
The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.
Related Links:
BD Biosciences
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Latest BioResearch News
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
Channels
Clinical Chemistry
view channel
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more
New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
Stroke affects more than 795,000 Americans each year, leaving many survivors with lasting motor, speech, and cognitive deficits. Because rehabilitation outcomes vary widely, clinicians still face challenges... Read more
NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies... Read more
Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
Lung cancer is often diagnosed at advanced stages because symptoms typically appear late, while participation in low-dose computed tomography (LDCT) screening remains low. Imaging can also produce false-positive... Read moreMolecular Diagnostics
view channel
Urine Genomic Test Detects More Than Nine in Ten Suspected Bladder Cancers
Urgent evaluation for suspected bladder cancer often sends patients to cystoscopy, an invasive and resource-intensive procedure, even though relatively few ultimately have cancer. This places pressure... Read more
Liquid Biopsy Test Predicts Tissue of Origin in Cancer of Unknown Primary
Cancers of unknown primary and other uncertain tumor presentations can complicate therapy selection, especially in community oncology settings where subspecialty pathology resources may be limited.... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more
Microbiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Pathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Industry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more
